Hyperoncotic Albumin Solution in Continuous Renal Replacement Therapy Patients.

Area of Science:

• Nephrology
• Critical Care Medicine
• Pharmacology

Background:

• Continuous renal replacement therapy (RRT) is a critical intervention for critically ill patients.
• Human albumin solution (HAS) is frequently administered in intensive care units.
• The use of varying concentrations of HAS, particularly hyperoncotic 20% HAS, requires careful evaluation in RRT patients.

Purpose of the Study:

• To investigate the association of hyperoncotic (20%) human albumin solution (HAS) with patient outcomes.
• To compare outcomes in critically ill patients receiving continuous renal replacement therapy (RRT) treated with 20% HAS versus 4% HAS.

Main Methods:

• Analysis of data from the Randomized Evaluation of Normal versus Augmented Level (RENAL) RRT trial.
• Comparison of patient outcomes, including mortality and RRT independence, based on HAS administration (4% only, 20% only, or both).
• Utilized Cox proportional hazards regression to assess the impact of 20% HAS exposure on mortality and RRT recovery.

Main Results:

• Of 1,508 patients, 771 received albumin, with varying concentrations used.
• Patients receiving 20% HAS experienced a more negative mean daily fluid balance compared to those receiving 4% HAS only.
• Exposure to 20% HAS was not independently associated with increased 90-day mortality or prolonged RRT dependence.

Conclusions:

• Albumin administration in varying concentrations is common in RENAL trial patients.
• While 20% HAS was associated with a more negative fluid balance, it did not independently increase mortality or RRT dependence compared to 4% HAS.
• These findings suggest that 20% HAS can be used in RRT patients without a significant increase in adverse outcomes.